新型口服磷结合剂研究进展  

Research progress in novel oral phosphorus binders

作　　者：赵岚 陈元浩 韩颖超[1] ZHAO Lan;CHEN Yuan-hao;HAN Ying-chao(State Key Laboratory of Advanced Technology for Material Synthesis and Processing,Wuhan University of Technology,Wuhan 430070,China)

机构地区：[1]武汉理工大学材料复合新技术国家重点实验室,武汉430070

出　　处：《中国新药杂志》2024年第18期1897-1905,共9页Chinese Journal of New Drugs

基　　金：湖北省国际科技合作项目(2023EHA056)。

摘　　要：使用磷结合剂控制血清磷是高磷血症患者治疗的重要手段。传统口服磷结合剂氢氧化铝具有潜在的铝毒性而被淘汰,碳酸钙等钙基磷结合剂存在引起高钙血症且所需药片剂量相对较大、患者依从性较差的问题。因此,具有高磷结合能力、毒副作用低且每日片剂负荷小特点的新型口服磷结合剂的研究尤为重要。本文根据非铝、非钙新型磷结合剂的特点,对其进行分类论述,包括制备工艺、临床安全性和有效性,并对新型口服磷结合剂的发展趋势进行展望。The control of serum phosphorus using phosphate binders is an important tool in the treatment of patients with hyperphosphatemia.Traditional phosphate binder aluminum hydroxide has been phased out due to potential aluminum toxicity,and calcium-based phosphorus binders such as calcium carbonate may cause hypercalcemia,require relatively large dose of tablets,and poor patient compliance.Therefore,it is particularly important to study the novel oral phosphorus binders with high phosphorus binding ability,low toxic side effects and small daily tablet load.Based on the characteristics of non-aluminum and non-calcium phosphorus binders,the novel oral phosphorus binders were classified and discussed in this article,including preparation process,clinical safety and effectiveness.And the development trend of novel oral phosphorus binders was prospected.

关 键 词：磷结合剂 高磷血症 碳酸镧 枸橼酸铁 司维拉姆 

分 类 号：R979.9[医药卫生—药品]